Abstract is: Georgia Chenevix-Trench FAA, FAHMS (born 8 February 1959) is an Australian cancer researcher who investigates genetic predispositions to cancer. Chenevix-Trench was born in Nairobi, Kenya. She received her undergraduate degree (BSc(Hons)) in 1980 from the Department of Genetics at Trinity College in Ireland and was subsequently awarded her PhD in 1985 from the Department of Human Genetics at the Medical College of Virginia, USA. and in 1986 she commenced her post-doctoral work there. In 1989 she moved to Australia where she started working as a research officer at the Queensland Institute of Medical Research (QIMR). She currently works at the QIMR Berghofer Medical Research Institute, where she heads a cancer genetics research lab. Chenevix-Trench has published over 400 papers in peer reviewed journals and has been actively involved in science education and communication. She was elected to the Australian Academy of Science in 2014, for her work on the genetics of breast, ovarian and other cancers, including showing that mutations in the ATM gene confer moderate risks for breast cancer. In 2015 she was elected Fellow of the Australian Academy of Health and Medical Sciences. She was awarded the Suzanne Cory Medal and Lecture by the Australian Academy of Science in 2022.
human | Q5 |
P6178 | Dimensions author ID | 01012310162.58 |
P646 | Freebase ID | /m/011q64xw |
P496 | ORCID iD | 0000-0002-1878-2587 |
P4638 | The Peerage person ID | p3558.htm#i35574 |
P166 | award received | Suzanne Cory Medal | Q112136264 |
Fellow of the Australian Academy of Science | Q59260322 | ||
Fellow of the Australian Academy of Health and Medical Sciences | Q59771619 | ||
P40 | child | Hilary Chenevix Martin | Q75486215 |
Felicity Chenevix Martin | Q75486216 | ||
P27 | country of citizenship | Australia | Q408 |
P69 | educated at | Trinity College Dublin | Q258464 |
Virginia Commonwealth University School of Medicine | Q7906670 | ||
P108 | employer | QIMR Berghofer Medical Research Institute | Q7270958 |
P22 | father | Charles Pocklington Chenevix Trench | Q52161468 |
P735 | given name | Georgia | Q378694 |
Georgia | Q378694 | ||
P463 | member of | Australian Academy of Science | Q514105 |
P25 | mother | Mary Elizabeth Kirkbride | Q75281691 |
P106 | occupation | geneticist | Q3126128 |
P21 | sex or gender | female | Q6581072 |
P26 | spouse | Nicholas Gordon Martin | Q75281807 |
Q91209246 | "I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival |
Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
Q51569689 | A BRCA1 promoter variant (rs11655505) and breast cancer risk. |
Q35656649 | A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of Telomerase |
Q59349476 | A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants |
Q92224274 | A Mendelian randomization analysis of circulating lipid traits and breast cancer risk |
Q57265744 | A Systematic Approach to Analysing Gene-Gene Interactions: Polymorphisms at the Microsomal Epoxide Hydrolase EPHX and Glutathione S-transferase GSTM1, GSTT1, and GSTP1 Loci and Breast Cancer Risk |
Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
Q57250674 | A common coding variant in CASP8 is associated with breast cancer risk |
Q33698648 | A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy |
Q37272982 | A genome wide linkage search for breast cancer susceptibility genes |
Q37332232 | A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk |
Q33747778 | A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. |
Q29417084 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. |
Q36013881 | A genome-wide association study of caffeine-related sleep disturbance: confirmation of a role for a common variant in the adenosine receptor |
Q35195145 | A large, dominant pedigree of atrioventricular septal defect (AVSD): exclusion from the Down syndrome critical region on chromosome 21. |
Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
Q40155430 | A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP. |
Q57265807 | A protein-truncating mutation inCYP17A1 in three sisters with early-onset breast cancer |
Q34369388 | A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia |
Q85312916 | A role for common genomic variants in the assessment of familial breast cancer |
Q119213000 | A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer |
Q74459364 | A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers |
Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
Q33947899 | ABCA transporter gene expression and poor outcome in epithelial ovarian cancer |
Q45903986 | ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. |
Q37227494 | ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas |
Q35959358 | ATM and genome maintenance: defining its role in breast cancer susceptibility |
Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
Q64458508 | Abstract 5493: Genome-wide study of carboplatin and paclitaxel disposition in ovarian cancer patients |
Q63681770 | Abstract P6-10-06: Rational combination therapy against triple-negative breast cancer |
Q38406780 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study |
Q52647897 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. |
Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
Q71733519 | Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus |
Q45067214 | Allelic variation of the c-raf-1 oncogene in non-Hodgkin's lymphoma |
Q41276116 | Allelic variation of the c-raf-1 proto-oncogene in human lymphoma and leukemia. |
Q51196598 | Altered regulation of c-myc in an HL-60 differentiation resistant subclone, HL-60-1E3. |
Q53465106 | An Alu VpA marker on chromosome I demonstrates that replication errors manifest at the adenoma-carcinoma transition in sporadic colorectal tumors. |
Q34623703 | An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) |
Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
Q42371458 | Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci |
Q46464326 | Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients |
Q85077261 | Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients |
Q34480599 | Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource |
Q44284336 | Analysis of gene amplification in head-and-neck squamous-cell carcinoma |
Q73259331 | Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations |
Q36831854 | Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome |
Q36623673 | Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma |
Q24656704 | Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer |
Q28185257 | Analysis of the transcription regulator, CNOT7, as a candidate chromosome 8 tumor suppressor gene in colorectal cancer |
Q57269082 | Androgen receptor exon 1 cag repeat length and risk of ovarian cancer |
Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
Q73433559 | Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers |
Q63681771 | Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges |
Q42763529 | Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic? |
Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
Q34613673 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study |
Q30276986 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes |
Q35156876 | Assessment of hepatocyte growth factor in ovarian cancer mortality |
Q47397042 | Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. |
Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
Q37684409 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer |
Q28138778 | Assignment of the human slit homologue SLIT2 to human chromosome band 4p15.2 |
Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
Q27851709 | Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer |
Q84635142 | Association between KRAS rs61764370 and triple-negative breast cancer--a false positive? |
Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
Q37200998 | Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study |
Q37151872 | Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. |
Q37292963 | Association of ESR1 gene tagging SNPs with breast cancer risk |
Q91271723 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness |
Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
Q46707380 | Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis |
Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
Q99609984 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer |
Q72671791 | Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers |
Q34801008 | Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
Q39423088 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study |
Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
Q57391849 | Atopy in Australia |
Q36393308 | BCoR-L1 variation and breast cancer |
Q57306053 | BRAF polymorphisms and the risk of ovarian cancer of low malignant potential |
Q64039257 | BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry |
Q33337136 | BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression |
Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
Q57306056 | BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk |
Q35896230 | BamHI RFLP of the inhibin beta B (INHBB) chain gene on chromosome 2. |
Q42493776 | Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication |
Q42462369 | Basal cell carcinomas, coarse sparse hair, and milia |
Q68197898 | Basal cell naevus syndrome |
Q40527413 | BcII RFLP of the plasminogen activator inhibitor type 2 gene (PLANH) on chromosome 18q21-q23. |
Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
Q100457582 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk |
Q114182645 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores |
Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
Q37410693 | Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab |
Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
Q37839530 | Breast cancer stem cells: treatment resistance and therapeutic opportunities |
Q47684602 | CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer |
Q36998293 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration |
Q24810733 | CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study |
Q73088381 | CYP17 promoter polymorphism and breast cancer in Australian women under age forty years |
Q73666685 | CYP17 promotor polymorphism and ovarian cancer risk |
Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
Q114657791 | Cancer Risks Associated With and Pathogenic Variants |
Q92636519 | Candidate Causal Variants at the 8p12 Breast Cancer Risk Locus Regulate DUSP4 |
Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q35693892 | Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci |
Q41456461 | Cep55 regulates embryonic growth and development by promoting Akt stability in zebrafish |
Q52691103 | Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient. |
Q96962174 | Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
Q38309212 | Characterization of the breast cancer associated ATM 7271T>G (V2424G) mutation by gene expression profiling |
Q92475989 | Chromatin interactome mapping at 139 independent breast cancer risk signals |
Q78845343 | Chromosome 8 genetic analysis and phenotypic characterization of 21 ovarian cancer cell lines |
Q45077098 | Chromosome analysis of 30 cases of non-Hodgkin's lymphoma |
Q35782435 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer |
Q35447780 | Classification of BRCA1 missense variants of unknown clinical significance |
Q35196271 | Cleft lip with or without cleft palate: associations with transforming growth factor alpha and retinoic acid receptor loci |
Q57306048 | Clinical Classification ofBRCA1andBRCA2DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis—A Report From the kConFab Investigators |
Q36080881 | Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region |
Q37657957 | Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer |
Q94486442 | Combined associations of a polygenic risk score and classical risk factors with breast cancer risk |
Q35668946 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk |
Q57265809 | Common Polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not Associated with Breast Cancer Risk |
Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
Q34126314 | Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer |
Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
Q24655824 | Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q81621687 | Common chromosomal fragile site FRA16D mutation in cancer cells |
Q37732823 | Common genetic variants and cancer risk in Mendelian cancer syndromes |
Q33742096 | Common genetic variants and modification of penetrance of BRCA2-associated breast cancer |
Q34949394 | Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers |
Q47139520 | Common genomic variants associated with breast cancer predict the risk of second primary breast cancer diagnosis. |
Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
Q33947829 | Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q36393232 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers |
Q29417145 | Common variants at 19p13 are associated with susceptibility to ovarian cancer |
Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q36255665 | Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer |
Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
Q34213403 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers |
Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
Q33851325 | Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis |
Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
Q37155532 | Consortium analysis of 7 candidate SNPs for ovarian cancer |
Q96123636 | Copy Number Variation and Ovarian Cancer Risk-Letter |
Q45950681 | Correction: BCoR-L1 variation and breast cancer. |
Q57266620 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer |
Q45793899 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. |
Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
Q91090014 | Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
Q53298473 | Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. |
Q70182016 | Cytogenetic and molecular genetic studies of a patient with atypical lymphoid hyperplasia |
Q42482417 | DHPLC analysis of patients with Nevoid Basal Cell Carcinoma Syndrome reveals novel PTCH missense mutations in the sterol-sensing domain |
Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
Q33708624 | DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status |
Q63372140 | DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status |
Q37685729 | DNA mismatch repair gene MSH6 implicated in determining age at natural menopause |
Q41672068 | De novo mutations of the Patched gene in nevoid basal cell carcinoma syndrome help to define the clinical phenotype |
Q36622573 | Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas |
Q40760869 | Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). |
Q96590073 | Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) |
Q40707128 | Distinct phenotype in maternal uniparental disomy of chromosome 14. |
Q22066027 | Dominant Negative ATM Mutations in Breast Cancer Families |
Q43924266 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. |
Q57265812 | Double-Strand Break Repair Gene Polymorphisms and Risk of Breast or Ovarian Cancer |
Q33824208 | ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study |
Q36245609 | Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers |
Q67975809 | Elevation of follicular phase inhibin and luteinizing hormone levels in mothers of dizygotic twins suggests nonovarian control of human multiple ovulation |
Q24633316 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer |
Q112637570 | Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer |
Q57250672 | Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk |
Q57319395 | Erratum: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer |
Q57306046 | Erratum: Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium |
Q34767345 | Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer |
Q33932856 | Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium |
Q36966218 | Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study |
Q34659939 | Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis |
Q99720321 | Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses |
Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
Q21144976 | Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot" |
Q36352389 | Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers |
Q37745041 | Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
Q34806825 | Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. |
Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
Q34613604 | Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers |
Q34687073 | Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study |
Q35643949 | Evidence for an association between nonsyndromic cleft lip with or without cleft palate and a gene located on the long arm of chromosome 4. |
Q57287527 | Evidence for microsatellite instability in bilateral breast carcinomas |
Q37347027 | Evidence of a genetic link between endometriosis and ovarian cancer |
Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
Q25257572 | Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms |
Q54648951 | Exclusion of APC and MCC as the gene defect in one family with familial juvenile polyposis. |
Q38845261 | Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk |
Q33863235 | Exploring the link between MORF4L1 and risk of breast cancer |
Q42490438 | Expression of beta-catenin, a key mediator of the WNT signaling pathway, in basal cell carcinoma |
Q42483687 | Expression of p53 in arsenic-related and sporadic basal cell carcinoma |
Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
Q73443345 | Fertility and incidence of KRAS2 mutations in borderline ovarian adenocarcinomas |
Q42484642 | Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas |
Q28243330 | Fine genetic mapping of the gene for nevoid basal cell carcinoma syndrome |
Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
Q44116963 | Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer |
Q48030071 | Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. |
Q70571548 | Frequent loss of heterozygosity on chromosome 14 occurs in advanced colorectal carcinomas |
Q58025019 | Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus |
Q51843102 | Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. |
Q91016919 | Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. |
Q114182808 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element |
Q42366538 | Functional dissection of breast cancer risk-associated TERT promoter variants |
Q71767608 | Functional evidence for a colorectal cancer tumor suppressor gene at chromosome 8p22-23 by monochromosome transfer |
Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
Q58047816 | Functional polymorphisms in the TERT promoter are associated with risk of serious ovarian and breast cancer |
Q34031757 | Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers |
Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
Q43146116 | Further evidence for an association between genetic variation in transforming growth factor alpha and cleft lip and palate |
Q35195046 | Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: linkage and loss of heterozygosity. |
Q36956156 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer |
Q34205748 | Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome |
Q52828093 | Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53. |
Q33622653 | Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay |
Q63372138 | Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression |
Q36175072 | Gene-panel sequencing and the prediction of breast-cancer risk |
Q62583319 | Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk |
Q57306006 | Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical Significance |
Q35999323 | Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study |
Q108609948 | Genetic insights into biological mechanisms governing human ovarian ageing |
Q29417068 | Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study |
Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
Q34453723 | Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium |
Q34955369 | Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk |
Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
Q43167965 | Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants |
Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
Q92387949 | Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent |
Q95304100 | Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children |
Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
Q36218993 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium |
Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
Q36352038 | Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM |
Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
Q92534414 | Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women |
Q37202841 | Genome-wide association study for ovarian cancer susceptibility using pooled DNA. |
Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
Q24645441 | Genome-wide association study identifies novel breast cancer susceptibility loci |
Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
Q48171906 | Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer |
Q33778612 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. |
Q59566871 | Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility |
Q72649470 | Genomic instability occurs in colorectal carcinomas but not in adenomas |
Q44734673 | Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. |
Q33901605 | Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development |
Q64083344 | Germline deletion of in familial acute lymphoblastic leukemia |
Q35114576 | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer |
Q36916243 | Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer |
Q114182677 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis |
Q42481341 | Glutathione S-transferase GSTM1 null genotype is not overrepresented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma |
Q71888275 | Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset |
Q35106767 | Growing recognition of the role for rare missense substitutions in breast cancer susceptibility |
Q55333927 | Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. |
Q34173413 | HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer |
Q35382206 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers |
Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
Q35551911 | Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. |
Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
Q36566003 | High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations |
Q119213179 | High-throughput allelic expression imbalance analyses identify candidate breast cancer risk genes |
Q35889267 | Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors |
Q33551425 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study |
Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
Q37006170 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. |
Q36465306 | Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? |
Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
Q112717190 | Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer |
Q59291228 | Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy |
Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
Q47161199 | Identification of new breast cancer predisposition genes via whole exome sequencing |
Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
Q36014067 | Identification of novel genetic markers of breast cancer survival |
Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
Q97074448 | Immune Cell Associations with Cancer Risk |
Q33227516 | Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses |
Q71920478 | Increased expression of the NME1 gene is associated with metastasis in epithelial ovarian cancer |
Q37410472 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women |
Q37684424 | Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration |
Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
Q38385463 | Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance |
Q30275132 | Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci |
Q34081324 | Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer |
Q30277784 | Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer |
Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
Q60182876 | Is Schizophrenia a Risk Factor for Breast Cancer?—Evidence From Genetic Data |
Q34490781 | Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. |
Q33917578 | Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer |
Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
Q37725393 | Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome |
Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
Q91534941 | LobSig is a multigene predictor of outcome in invasive lobular carcinoma |
Q28260002 | Localization of the gene for human proliferating nuclear antigen/cyclin by in situ hybridization |
Q73870254 | Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas |
Q36079621 | Loss of heterozygosity on the long arm of chromosome 11 in colorectal tumours |
Q36616262 | Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals |
Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
Q34354426 | Lung cancer: intragenic ERBB2 kinase mutations in tumours |
Q43145479 | Lymphoblastoid cell lines from frozen whole blood: a quick and economical safeguard for linkage analysis |
Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
Q40556912 | Mapping of a candidate colorectal cancer tumor-suppressor gene to a 900-kilobase region on the short arm of chromosome 8. |
Q42439709 | Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. |
Q92860654 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers |
Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
Q97528612 | Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival |
Q33555064 | Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer |
Q55387708 | Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. |
Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
Q48221533 | Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology |
Q37362211 | Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers |
Q57305979 | Molecular Characterization and Cancer Risk Associated with BRCA1 and BRCA2 Splice Site Variants Identified in Multiple-Case Breast Cancer Families |
Q57306007 | Molecular characterization and cancer risk associated withBRCA1 andBRCA2 splice site variants identified in multiple-case breast cancer families |
Q53829480 | Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. |
Q34736858 | Most common 'sporadic' cancers have a significant germline genetic component |
Q24310445 | Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident |
Q35802557 | MspI RFLP of FSHB on chromosome 11p |
Q42514809 | Multidimensional phenotyping of breast cancer cell lines to guide preclinical research |
Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
Q25257392 | Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer |
Q64386822 | Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families |
Q44341959 | Mutation analysis of five candidate genes in familial breast cancer |
Q40426350 | Mutation and expression analysis of LZTS1 in ovarian cancer |
Q50613227 | Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. |
Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
Q42450636 | Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women |
Q27860760 | Mutations of the BRAF gene in human cancer |
Q24336457 | Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome |
Q52675313 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. |
Q24629025 | NcoI RFLP of the human LHRH gene on chromosome 8p |
Q26799669 | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk |
Q40678901 | Nevoid basal cell carcinoma syndrome: review of 118 affected individuals |
Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
Q97430909 | Nicholas Gordon Martin |
Q30275832 | No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival |
Q37237352 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study |
Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
Q54396803 | No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. |
Q24800108 | No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer |
Q74736372 | No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms |
Q42452827 | No evidence for the H133Y mutation in SONIC HEDGEHOG in a collection of common tumour types |
Q51699099 | No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. |
Q37308596 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk |
Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
Q24806182 | No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer |
Q43589119 | No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer |
Q92476025 | Non-coding RNAs underlie genetic predisposition to breast cancer |
Q89927576 | Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D |
Q47298863 | Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium |
Q38400931 | Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes |
Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
Q33586121 | Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer |
Q40070779 | Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families. |
Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
Q112572520 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes |
Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
Q29547841 | Patterns of somatic mutation in human cancer genomes |
Q35177861 | Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients |
Q34522502 | Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant |
Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
Q97524107 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants |
Q33891803 | Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium |
Q24648412 | Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women |
Q31835337 | Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype |
Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
Q33921008 | Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium |
Q33747831 | Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium |
Q34780052 | Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q45062920 | Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry |
Q96431220 | Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer |
Q40216095 | Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability |
Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
Q55094933 | Primary treatment patterns in women recruited to the Australian Ovarian Cancer Study. |
Q35223238 | Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort |
Q57306049 | Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies |
Q45187094 | Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. |
Q36614790 | Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis |
Q96027123 | Prognostic gene expression signature for high-grade serous ovarian cancer |
Q57265866 | Prohibitin 3′ untranslated region polymorphism and breast cancer risk in Australian women |
Q35223068 | Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer |
Q35879159 | PstI RFLP of the CGB gene |
Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
Q36512097 | RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies |
Q36009422 | RAD51B in Familial Breast Cancer |
Q57306054 | RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women |
Q33917622 | Rad51 supports triple negative breast cancer metastasis |
Q114182625 | Rare germline copy number variants (CNVs) and breast cancer risk |
Q73115092 | Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours |
Q35608690 | Rare variants in the ATM gene and risk of breast cancer |
Q37373918 | Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer |
Q36615915 | Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma |
Q28365024 | Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas |
Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
Q48018693 | Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer |
Q57269231 | Reproductive hormone genes in mothers of spontaneous dizygotic twins: an association study |
Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
Q36467883 | Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls |
Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
Q37624504 | Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10 |
Q37453871 | Role of genetic polymorphisms and ovarian cancer susceptibility |
Q37188838 | Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium |
Q97883645 | SNPs in lncRNA Regions and Breast Cancer Risk |
Q59270771 | Searching for BRCA3 by exome sequencing |
Q63681731 | Sequence variants ofDLC1 in colorectal and ovarian tumours |
Q36089391 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer |
Q61118451 | Shared heritability and functional enrichment across six solid cancers |
Q64004349 | Shared heritability and functional enrichment across six solid cancers |
Q41499061 | Simple repeat polymorphism at the D9S151 locus. |
Q37151786 | Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer |
Q54254464 | Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell. |
Q71254196 | Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer |
Q70147998 | Somatic rearrangement of the c-myc oncogene in primary human diffuse large-cell lymphoma |
Q44039296 | Spastic paresis, glaucoma and mental retardation--a probable autosomal recessive syndrome? |
Q42463910 | Subtypes of familial breast tumours revealed by expression and copy number profiling |
Q38955844 | Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors |
Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
Q50690518 | Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. |
Q37025837 | Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families |
Q57250694 | The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
Q46594966 | The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis |
Q36921422 | The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin |
Q43754304 | The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. |
Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
Q33675997 | The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q57265871 | The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer |
Q42084911 | The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls |
Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
Q34115636 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers |
Q52673733 | The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. |
Q46950536 | The MnSOD Val9Ala polymorphism, dietary antioxidant intake, risk and survival in ovarian cancer (Australia). |
Q37578078 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers |
Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
Q37401496 | The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q24797305 | The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q34306268 | The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes |
Q59292171 | The challenges of finding the gene responsible for a rare, autosomal dominant gastric cancer susceptibility syndrome |
Q42487051 | The diagnostic implication of falcine calcification on plain skull radiographs of patients with basal cell naevus syndrome and the incidence of falcine calcification in their relatives and two control groups |
Q42457755 | The effects of splice site mutations in patients with naevoid basal cell carcinoma syndrome |
Q34325260 | The human growth-arrest-specific gene GAS1 maps outside the candidate region of the gene for nevoid basal cell carcinoma syndrome |
Q55445982 | The importance of using public data to validate reported associations. |
Q24806016 | The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia |
Q43545828 | The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer. |
Q39657980 | The molecular genetics of human non-Hodgkin's lymphoma |
Q93063911 | The molecular origin and taxonomy of mucinous ovarian carcinoma |
Q40455895 | The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS. |
Q43993679 | The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women. |
Q57306058 | The prohibitin 3′ untranslated region polymorphism is not associated with risk of ovarian cancer |
Q35024008 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
Q38435382 | The role of glutathione-S-transferase polymorphisms in ovarian cancer survival |
Q92832186 | The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries |
Q42489919 | The spectrum of patched mutations in a collection of Australian basal cell carcinomas |
Q43829398 | The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women. |
Q55443510 | The use of the Illumina FFPE Restoration Protocol to obtain suitable quality DNA for SNP-based CGH– a pilot study. |
Q47397232 | Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach |
Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
Q38483754 | Transfer of chromosome 8 into two breast cancer cell lines: total exclusion of three regions indicates location of putative in vitro growth suppressor genes |
Q46417337 | Translating Germline Cancer Risk into Precision Prevention |
Q39169737 | Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor |
Q57390853 | Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer |
Q51974477 | Two ATM variants and breast cancer risk. |
Q53488352 | UV induction of transforming growth factor alpha in melanoma cell lines is a posttranslational event. |
Q47830753 | Urokinase receptor genotypes in colorectal cancer. |
Q35602598 | Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib |
Q37081074 | Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium |
Q56342454 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility |
Q33847791 | Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer |
Q35012867 | Variation in the RAD51 gene and familial breast cancer |
Q86450533 | WGS and targetted sequencing in acute lymphoblastic leukemia identifies putative enhancer mutation associated with over-expression of a growth factor |
Q59078721 | What makes a good PhD student? |
Q37144248 | What's in a cancer syndrome? Genes, phenotype and pathology |
Q34177267 | Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk |
Q98881532 | eQTL Colocalization Analyses Identify NTN4 as a Candidate Breast Cancer Risk Gene |
Q44458999 | kConFab: a research resource of Australasian breast cancer families. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer |
Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Q56334023 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology |
Q75281807 | Nicholas Gordon Martin | spouse | P26 |
Georgia Chenevix-Trench | wikipedia |
Search more.